Relugolix. GnRH (LHRH) receptor antagonist, Treatment of uterine fibroids, Treatment of endometriosis-related pain, Treatment of prostate cancer

Amro Elsharoud, Mohamed Ali, Ayman Al-Hendy
In: Drugs of the Future · 2019 · vol. 44(2) , pp. 131 · doi:10.1358/dof.2019.44.2.2927590 · W2922106414
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Relugolix, a GnRH receptor antagonist, is an orally active medication approved for treating uterine fibroids, endometriosis-related pain, and prostate cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK